US Generics & Biosimilars / Five Takeaways from Access! 2021
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the…
Top Stories
Southeast Asia / Kalbe Underwhelms in Indonesia; Novavax Looks to Filipino Vaccine Manufacturing; Thai Cannabis Market Boom
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
Singapore / A Myriad of Biotech Financing Strategies
Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy,…
MEA / Georg Schroeckenfuchs of Novartis: ‘Shooting for the Moon’ in Saudi
33-year pharma industry veteran Georg Schroeckenfuchs currently heads up the vast Middle East & Africa (MEA)…
Mexico / Bayer Targets Cancer; Novartis Gets Aggressive; J&J Vaccines Arrive; Doctors Denied Jabs
The latest news from Mexican pharma, including Bayer’s big bet on oncology and Novartis’ aggressive expansion…
Aducanumab Approval / Opening the Floodgates for a New Era of Alzheimer’s Treatment?
With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval…
In Conversation
Ng Huck Hui – Assistant Chief Executive, Biomedical Research Council, Agency for Science, Technology and Research (A*STAR), Singapore
Professor Ng Huck Hui of A*Star’s Biomedical Research Council outlines the evolution of Singapore’s science and technology research and innovation ecosystem over the past 20 years and why the country is now focusing on translational science and building up enterprise. During the past 20 years, we have built clusters like Biopolis, universities and institutions and so on. The piece…
Latest Reports
Focus on Switzerland
Switzerland’s Upcoming Cost Containment Packages:…
While once considered the land of milk and honey within Europe in terms of…
Switzerland’s Quest for Alternatives to Animal Testing of…
Animal testing for medicinal purposes is back under the spotlight in Switzerland…
Switzerland Biotech Listing Snapshot 2021
The SXI Bio & MedTech Index outperformed the Swiss Performance Index (SPI)…
MSD Switzerland AVP on Recent Zurich R&D Investment
In February 2020, US giant MSD announced the launch of a new site in Zurich…
Read more: Switzerland >>
Focus on China
China Pharma News: BioNTech-Fosun JV; Patent Law Revamp;…
The latest news from Chinese pharma, including an overhaul of the country’s…
China: EpimAb Looks to 2022 IPO & Global Leadership in…
Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb…
APAC: Generic Penetration by Country
Generics penetration in the Asia-Pacific region by country for 2018. A full 90.3…
Roche Hoping to Spearhead ‘Created in China’ Push with…
In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai,…
Read more: China >>
Focus on Europe
UK Pharma News: Fastest Growing Private Pharmacos; GSK…
The latest UK pharma news, including how new investment in GSK stands to reshape…
Spanish Pharma News: Market Growth; Esteve’s US Expansion;…
The latest from Spanish pharma, including the acquisition of PTS by a private…
Switzerland’s Upcoming Cost Containment Packages:…
While once considered the land of milk and honey within Europe in terms of…
MSD Switzerland AVP on Recent Zurich R&D Investment
In February 2020, US giant MSD announced the launch of a new site in Zurich…
Read more: Europe >>
Focus on Singapore
APAC: Diagnostics in the Post-COVID Era
COVID-19 has pushed diagnostics to the forefront of healthcare conversations…
Singapore: A Myriad of Biotech Financing Strategies
Since 2000, when Singapore first positioned biomedical research as the fourth…
APAC: How Precision Medicine is Transforming the Oncology…
Asia-Pacific, as home to 50 percent of the world’s new cancer cases each year…
Singapore: Finding the Right Pharma Talent Post-COVID
Singapore – despite its modest USD 1.22 billion domestic market – has long…
Read more: Singapore >>
Focus on Vaccines
Sputnik V: A Brief History of Russia’s Controversial Viral…
Although Russian authorities received heavy criticism for approving the Sputnik…
IP PACT: A Journey, Not a Destination
The issue of COVID-19 vaccine access in developing nations has thrust…
Mexico Pharma News: Bayer Targets Cancer; Novartis Gets…
The latest news from Mexican pharma, including Bayer’s big bet on oncology and…
Germany Pharma News: Merck KGaA Expecting More COVID-Related…
The latest news from German pharma, including a new US leadership team and more…
Read more: Vaccines >>
Focus on USA
US U-Turn as Biden Pledges Support for Waiver on COVID-19…
In a shock move, Joe Biden’s administration looks set to support a waiver on…
US Generics & Biosimilars: Five Takeaways from Access!…
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five…
Aducanumab Approval: Opening the Floodgates for a New Era of…
With the US FDA’s controversial recent decision to approve Biogen and…
USA: Importance of the Patient Voice in Drug Development:…
Writing in the May edition of DIA’s Global Forum magazine, Erica Lyons, Sarrit…
Read more: USA >>
Focus on MEA
Saudi Arabia: SFDA CEO Sets Out Strategic Priorities
In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey,…
MENA Pharma News: Egypt Opens ‘Pharma City’;…
The latest Middle East and North Africa (MENA) pharma, including Egypt’s…
5 Things to Know about Saudi Arabian Pharma
A rundown of five things to know about the USD 8.2 billion Saudi pharma market,…
The Skills That Regional Pharma Leaders Need in the Middle…
Mohamed Nasser, Amgen’s general manager for the vast Middle East & Africa…